Inomagen Therapeutics

Inomagen Therapeutics is a preclinical-stage biotechnology company focused on developing non-viral gene therapies and a proprietary delivery system to treat atrial fibrillation (AFib). Founded with technology licensed from Northwestern University, the company utilizes a novel transvenous, catheter-based approach involving reversible electroporation to deliver naked plasmid DNA directly to the cardiac atrium. This method is designed to target underlying molecular mechanisms of AFib, such as electrical and structural remodeling, while minimizing off-target effects. By employing a procedure that mirrors existing catheter ablation, Inomagen aims to provide a safe, minimally invasive alternative to traditional therapies that often only address symptoms rather than root causes.

The company's work addresses the significant clinical need for improved AFib treatments, which remain a growing health challenge for aging populations. Inomagen’s platform, which has demonstrated proof-of-concept in large animal models, is also being positioned as a potential solution for other cardiac conditions, including ventricular arrhythmias and congestive heart failure, for which current viral-based delivery methods face challenges like toxicity. Backed by NIH grant funding and recognized in various life science competitions, Inomagen is currently advancing its lead program into IND-enabling studies to bring its targeted gene therapy approach to electrophysiologists and cardiac surgeons.